Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance
the link between CANCER and CARDIOVASCULAR CARDIO-
VASCULAR

DISEASE
NEWS
FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us
LATEST TWEETS

TKI related HT and other CV side efects by Javid Moslehi @CardioOncology #ESCcongress2019 @escardio #CardioOnc

And SUPERB and thoughtful editorial immediately after by Vandy's own Javid Moslehi et al. I read them both between patients today in clinic, great stuff.

Really proud of my VU Cardio-Onc colleagues!

Hank https://t.co/pPW0lsT6w5

Interesting to see this signal of cardiotoxicity with Amgen's MCL-1 inhibitor. @Amgen @AmgenOncology Will this extend to there MCL-1 inhibitors? @CellDeathLab @DrTonyLetai @JuneWRhee @HanZhuMD
https://t.co/RZ66QSgffV

Great talk by Dr. Joseph Opferman. Great to finally have the chance to meet! @DrTonyLetai @CellDeathLab @apoptosislab @JoanMonte